艾美(6660.HK)重磅大单品人二倍体狂犬疫苗获批临床,效价远高于已上市的人二倍体狂苗

格隆汇
Yesterday

AI带动的港股科技股行情持续热辣滚烫,生物科技是其中的热门板块,相关企业不断传出技术创新的利好。疫苗头部企业艾美疫苗(06660.HK)3月9日公告,其研发的迭代工艺高效价人二倍体狂犬疫苗已于近日获得国家药品监督管理局《药物临床试验批准通知书》。该产品是一款迭代升级的人二倍体狂犬疫苗,具有超高效价的明显特点,也是全球狂犬疫苗技术领域的一次重大迭代升级。动物试验表明,免疫后可产生高保护水平的抗体,在...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10